TargetMol

CCG-222740

Product Code:
 
TAR-T7764
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7764-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-2mg2mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-5mg5mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-1mL1 mL * 10 mM (in DMSO)£156.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-10mg10mg£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-25mg25mg£326.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-50mg50mg£464.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7764-100mg100mg£653.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CCG-222740 is an inhibitor of Rho/MRTF pathway
CAS:
1922098-69-8
Formula:
C23H19ClF2N2O3
Molecular Weight:
444.86
Pathway:
Cell Cycle/Checkpoint; MAPK; Cytoskeletal Signaling; Stem Cells; GPCR/G Protein
Purity:
0.9879
SMILES:
FC1(F)CC(CN(C1)C(=O)c1cccc(c1)-c1ccco1)C(=O)Nc1ccc(Cl)cc1
Target:
ROCK; Rho; Ras

References

Yu-Wai-Man C , Spencer-Dene B , Lee R M H , et al. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis[J]. Scientific Reports, 2017, 7(1):518.